

Expert viewpoints: novel vaccine adjuvants

- “We have to be extremely cautious because, as I say, I think the worst thing that could happen to the whole field is a vaccine with a novel adjuvant, some TLR agonist, for example, does actually get licensed and there are major issues around it. Afterwards, there are safety problems and the whole field is dead for the next 20 years or something. So the fact that we have major regulatory inertia, and I mean, obviously, it’s frustrating for those developing adjuvants, but it just has to be there.” – **Global opinion leader**
- “With the possible exception of the influenza vaccine, where I think the principal interest will be in dose sparing, antigen dose sparing, rather than anything else, I think it’s going to be extremely difficult to justify putting novel adjuvants into what we already have in vaccines that are working reasonably well.” – **Global opinion leader**
- “The areas of need [for new adjuvants] are the therapeutic vaccines, but again, even the FDA have said they’re not going to stand in the way of new adjuvant in a therapeutic vaccine, it’s only in the context of a prophylactic where up to 300 million people will be injected, so even a one in a million lethal side effect, in their view, is too much.”– **Global opinion leader**
- “I think from the community perspective, if you go on the web there is a lot anti-vaccine literature, a lot of it which is focused on the toxicity of aluminium and also obviously mercury based preservatives. Again, I think that’s an issue people would like not to have to deal with.” – **Global opinion leader**



About VacZine Analytics:

VacZine Analytics is a brand new research consultancy based in the United Kingdom. Its aim is to provide high-quality disease and commercial analysis to those working within or in collaboration with the vaccine and biologics industry.

With our product lines:

- ① DiseaseINFOPACK
- ① OpportunitySCAN
- ① MarketVIEW
- ① ExpertREACT

Our key focus is helping clients to build the case for developing new vaccines.

Disclaimer

All rights reserved

This licensed product (or part thereof) may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the publisher VacZine Analytics (a division of Assay Advantage Ltd).

The facts presented within this document, at the time of its production, were believed to be correct and were gathered in good faith from both primary and secondary sources. VacZine Analytics is not always in the position to assure that the facts are guaranteed. VacZine Analytics cannot be held liable for any actions based upon facts or recommendations presented within this document.



VacZine Analytics

Bringing life to vaccine strategy...

www.vacZine-analytics.com

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel. +44 (0) 1279 654514
e-mail: info@vacZine-analytics.com

© VacZine Analytics, 2007. All rights reserved.